Elena R. Blujdea

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Cerebrospinal Fluid Amyloid and Tau Biomarker Changes Across the Alzheimer Disease Clinical Spectrum.

Cerebrospinal Fluid Amyloid and Tau Biomarker Changes Across the Alzheimer Disease Clinical Spectrum.

Journal: JAMA network open

Published: July 10, 2025

CHIT1 and DDAH1 levels relate to amyloid-related imaging abnormalities risk profile in Alzheimer's disease patients.

CHIT1 and DDAH1 levels relate to amyloid-related imaging abnormalities risk profile in Alzheimer's disease patients.

Journal: Alzheimer's research & therapy

Published: April 11, 2025

Running therapy or antidepressants as treatments for immunometabolic depression in patients with depressive and anxiety disorders: A secondary analysis of the MOTAR study.

Running therapy or antidepressants as treatments for immunometabolic depression in patients with depressive and anxiety disorders: A secondary analysis of the MOTAR study.

Journal: Brain, behavior, and immunity

Published: August 12, 2024

Plasma and MRI biomarkers capture neuronal damage in former professional boxers.

Plasma and MRI biomarkers capture neuronal damage in former professional boxers.

Journal: Scientific reports

Published: July 01, 2024

Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies.

Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies.

Journal: Neurology

Published: June 03, 2024

Serum biomarkers as prognostic markers for Alzheimer's disease in a clinical setting.

Serum biomarkers as prognostic markers for Alzheimer's disease in a clinical setting.

Journal: Alzheimer's & dementia (Amsterdam, Netherlands)

Published: April 18, 2024

Plasma pTau181 and pTau217 predict asymptomatic amyloid accumulation equally well as amyloid PET.

Plasma pTau181 and pTau217 predict asymptomatic amyloid accumulation equally well as amyloid PET.

Journal: Brain communications

Published: November 17, 2023

Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts.

Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: October 02, 2023

Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes.

Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes.

Journal: Brain : a journal of neurology

Published: April 01, 2023

CSF proteomics in autosomal dominant Alzheimer's disease highlights parallels with sporadic disease.

CSF proteomics in autosomal dominant Alzheimer's disease highlights parallels with sporadic disease.

Journal: Brain : a journal of neurology

Published: January 24, 2023

A hidden layer of structural variation in transposable elements reveals potential genetic modifiers in human disease-risk loci.

A hidden layer of structural variation in transposable elements reveals potential genetic modifiers in human disease-risk loci.

Journal: Genome research

Published: March 14, 2021

Showing 1-11 of 11

Last Updated: 09/26/2026